APA (7th ed.) Citation

IE, K., OA, J., JE, G., JD, L., EP, M., JA, Z., . . . KT, F. (2022). Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology, 6, e2100424. https://doi.org/10.1200/PO.21.00424

Chicago Style (17th ed.) Citation

IE, Krop, et al. "Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I." JCO Precision Oncology 6 (2022): e2100424. https://doi.org/10.1200/PO.21.00424.

MLA (9th ed.) Citation

IE, Krop, et al. "Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I." JCO Precision Oncology, vol. 6, 2022, p. e2100424, https://doi.org/10.1200/PO.21.00424.